A Population-Based, Postlicensure Evaluation of the Safety of a Combination Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, and Inactivated Poliovirus Vaccine in a Large Managed Care Organization

UCLA Center for Vaccine Research, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Los Angeles, CA, USA.
PEDIATRICS (Impact Factor: 5.3). 01/2009; 122(6):e1179-85. DOI: 10.1542/peds.2008-1977
Source: PubMed

ABSTRACT Prelicensure studies of diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus vaccine suggested that there were higher rates of fever after its administration than when its component antigens were given separately.
We conducted an open, controlled, cohort study to evaluate selected potential adverse events after receipt of diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine in the Southern California Kaiser Permanente Health Care Plan. From April 2003 through June 2005, we identified 61,004 infants who received >or=1 dose of vaccine (120000 total doses). This group was compared with a previous cohort of 58,251 age-, gender-, and medical center-matched infants (116,637 doses) who received diphtheria, tetanus, acellular pertussis vaccine and separate doses of hepatitis B and inactivated poliovirus vaccines from January 2002 through March 2003. We compared the incidence of seizures, medically attended events that were associated with fever, and other selected adverse outcomes.
We identified 16 infants (8 with fever) who had a seizure in the diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus cohort and 15 infants (6 with fever) among control subjects in the 8-day period after receipt of any dose of vaccine. The incidence of all seizures or seizures associated with fever was not significantly different between cohorts. The incidence of medically attended events that were associated with fever in the 4-day period after any dose of vaccine was also similar in both cohorts. As well, no significant differences between the diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and control cohorts, were noted in the incidence of allergic reactions within 48 hours of any dose of vaccine, outpatient visits within 21 days, hospitalizations within 21 days, or death within 1 year.
We did not observe a statistically significant increase in any of several clinically important safety events after diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccination compared with a historical cohort who received separate component vaccines.


Available from: Joel I Ward, Sep 09, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Combination vaccines have improved the efficiency of delivery of new vaccines in low and middle-income countries. Post-authorization monitoring of adverse events (AEs) after vaccination with a liquid pentavalent DTwP-HepB-Hib combination vaccine was conducted in Guatemalan infants. A prospective observational safety study of the incidence of medical attended events (MAEs) and serious adverse events (SAEs) in children who received pentavalent and oral polio vaccines at 2, 4 and 6 months of age was conducted in two clinics at the Institute of Guatemala. Parents were contacted by telephone after each dose. All outpatient, emergency department visits, and hospitalizations were monitored. A self-controlled analysis was conducted to determine if there was evidence of increased risk of MAEs or SAEs following vaccines as compared to control time windows. Of 3000 recruited infants, 2812 (93.7%) completed the third dose and 2805 (93.5%) completed follow-up. Ten AEs in eight infants, of which four SAEs in four infants, were classified as related to the vaccine. Thirteen deaths were reported due to common illnesses of infancy, and none were judged to be related to the vaccine. The mortality rate (4.4 per 1000) was lower than expected for the population. The incidence-rate-ratio for healthcare visits was lower in post-vaccination time windows than for control windows; after the first vaccine dose, the rate ratios for the risk periods of 0-1, 2-6, and 7-30 days post-vaccination were 0.3, 0.5, and 0.7, respectively (all statistically significantly different from the reference value of 1.0 for the 31-60 day control period). The liquid pentavalent vaccine was associated with lower rates of health care visits and not associated with increases in SAEs or hospitalizations. Systems can be set up in low to middle income countries to capture all health care visits to monitor the safety of new vaccines.
    Vaccine 09/2013; 31(49). DOI:10.1016/j.vaccine.2013.09.015 · 3.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Reports of childhood epilepsies in temporal association with vaccination have had a great impact on the acceptance of vaccination programs by health care providers, but little is known about this possible temporal association and about the types of seizures following vaccinations. For these reasons the Italian League Against Epilepsy (LICE), in collaboration with other Italian scientific societies, has decided to generate Guidelines on Vaccinations and Epilepsy. The aim of Guidelines on Vaccinations and Epilepsy is to present recent unequivocal evidence from published reports on the possible relationship between vaccines and epilepsy in order to provide information about contraindications and risks of vaccinations in patients with epilepsy. The following main issues have been addressed: (1) whether contraindications to vaccinations exist in patients with febrile convulsions, epilepsy, and/or epileptic encephalopathies; and (2) whether any vaccinations can cause febrile seizures, epilepsy, and/or epileptic encephalopathies. Diphtheria-tetanus-pertussis (DTP) vaccination and measles, mumps, and rubella vaccination (MMR) increase significantly the risk of febrile seizures. Recent observations and data about the relationships between vaccination and epileptic encephalopathy show that some cases of apparent vaccine-induced encephalopathy could in fact be caused by an inherent genetic defect with no causal relationship with vaccination.
    Epilepsia 10/2013; 54(Suppl 7):13-22. DOI:10.1111/epi.12306 · 4.58 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To systematically review algorithms to identify seizure, convulsion, or epilepsy cases in administrative and claims data, with a focus on studies that have examined the validity of the algorithms. A literature search was conducted using PubMed and the Iowa Drug Information Service database. Reviews were conducted by two investigators to identify studies using data sources from the USA or Canada because these data sources were most likely to reflect the coding practices of Mini-Sentinel data partners. Eleven studies that validated seizure, convulsion, or epilepsy cases were identified. All algorithms included International Classification of Diseases, Ninth Revision, Clinical Modification code 345.X (epilepsy) and either code 780.3 (convulsions) or code 780.39 (other convulsions). Six studies included 333.2 (myoclonus). In populations that included children, 779.0 (convulsions in newborn) was also fairly common. Positive predictive values (PPVs) ranged from 21% to 98%. Studies that used nonspecific indicators such as presence of an electroencephalogram or anti-epileptic drug (AED) level monitoring had lower PPVs. In studies focusing exclusively on epilepsy as opposed to isolated seizure events, sensitivity ranged from 70% to 99%. Algorithm performance was highly variable, so it is difficult to draw any strong conclusions. However, the PPVs were generally best in studies where epilepsy diagnoses were required. Using procedure codes for electroencephalograms or prescription claims for drugs possibly used for epilepsy or convulsions in the absence of a diagnostic code is not recommended. Many newer AEDs require no drug level monitoring, so requiring an AED level monitoring procedure in algorithms to identify epilepsy is not recommended.
    Pharmacoepidemiology and Drug Safety 01/2012; 21 Suppl 1:183-93. DOI:10.1002/pds.2329 · 3.17 Impact Factor